ArticleTherapeutic delivery2025
Luliconazole bilosomal gel for treating fungal infection: development, optimization and antifungal activity.
Article in Therapeutic delivery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsLuliconazole is a class of imidazole that exhibits high antifungal activity. Luliconazole has drawbacks, such as low aqueous solubility and poor skin penetration.
methodsTo overcome these limitations, luliconazole-loaded bilosomes (LZBSs) were developed via ethanol injection, using soy lecithin, cholesterol, Span 60, and bile salt. A 2
resultsThe optimized batch of LZBS resulted in a vesicle size of 177.3 ± 0.00 nm with an entrapment efficacy of 90.0 ± 2.5 % and zeta potential of -54.8 ± 3.15 mV. TEM analysis confirmed the spherical shape of bilosome vesicles and ATR-FTIR results supported the formation of bilosomes without any interaction. LZBS was loaded into Carbopol gel (LZBS gel) and evaluated for in vitro and ex vivo drug release study; results showed extended release of 90.53 ± 7.89 % and 84.97 ± 5.58 %, respectively, up to 24 h. Antifungal study for LZBS gel demonstrated superior activity against Candida albicans as compared to marketed and pure drug.
conclusionThus, luliconazole-loaded bilosome gel proved to be effective against fungal infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.